Ganoderma lucidum polysaccharide inhibits HSC activation and liver fibrosis via targeting inflammation, apoptosis, cell cycle, and ECM-receptor interaction mediated by TGF-β/Smad signaling

Jan 5, 2023Phytomedicine : international journal of phytotherapy and phytopharmacology

Ganoderma lucidum polysaccharide may reduce liver scarring by targeting inflammation, cell death, cell growth, and tissue structure through TGF-β/Smad signaling

AI simplified

Abstract

GLP (150 and 300 mg/kg) significantly inhibited hepatic fibrogenesis and inflammation in CCl-treated mice.

  • Ganoderma lucidum polysaccharide (GLP) may exert anti-fibrotic effects via the TLR4/NF-κB/MyD88 signaling pathway.
  • GLP significantly reduced collagen I and alpha-smooth muscle actin (a-SMA) expressions, indicating inhibited hepatic stellate cell activation.
  • RNA-sequencing identified key pathways suppressed by GLP, including inflammation, apoptosis, and cell cycle regulation.
  • GLP showed a dual effect on apoptosis, inhibiting it in vivo while promoting it in vitro.
  • GLP treatment resulted in the attenuation of ECM-receptor interaction-related molecules, particularly integrins ITGA6 and ITGA8.
  • Inhibition of TGF-β/Smad signaling was observed, with reduced phosphorylations of Smad2 and Smad3 and increased Smad7 expression in HSC-T6 cells.

AI simplified

Full Text

Full text is available at the source.

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free